Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Stock data | 2023 | Change |
---|---|---|
Price | $116.24 | N/A |
Market Cap | $238.92B | N/A |
Shares Outstanding | 2.06B | -5.76% |
Employees | 101.70K | N/A |
Shareholder Equity | 46.75B | -21.33% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 5.12 | N/A |
P/B Ratio | 5.11 | N/A |
P/FCF | 20.41 | N/A |
POE | 0.00 | N/A |
Dividends | 2023 | Change |
---|---|---|
Dividend Yield | 3.04% | N/A |
Dividend per share | 3.5296 | N/A |
Dividend Payout Ratio | 0.4884 | N/A |
Growth | 2023 | Change |
---|---|---|
ROIC | 0.1749 | N/A |
CAPEX | -823.00M | N/A |
Return on Equity | 0.3177 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $46.66B | N/A |
Earnings | $14.85B | N/A |
Free Cash Flow | $11.71B | N/A |
Gross Margin | 0.7327 | N/A |
Operating Margin | 0.2094 | N/A |
Net income margin | 0.3183 | N/A |
FCF Margin | 0.2509 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $99.94B | N/A |
Total Debt | $26.35B | N/A |
Cash on Hand | $13.96B | N/A |
Debt to Equity | $1.14 | 16.52% |
Cash to Debt | 0.5299 | -20.55% |
POE | 0.0000 | N/A |
Current Ratio | $1.16 | -10.33% |
Other data | 2023 | Change |
---|---|---|
Buyback Yield | 0.0365 | N/A |